Clovis Oncology's surging stock price gave the company the value it needed to acquire EOS for $10m in cash and $190m in Clovis common shares, and to access the private Italian firm's cancer drug lucitanib, which Boulder, Colorado-based Clovis has been tracking for two years.
"We have been interested in lucitanib for some time and are pleased to have acquired EOS to add this program...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?